AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
 |
- Gain attention as an alternative technology to the malaria HRP-2/3 gene deletion problem in Africa
- Prepare a bridgehead to enter the U.S. market by securing a credible reference
YONGIN, South Korea, June 17, 2024 /PRNewswire/ -- On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by U.S. Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).
The project will involve 2,000 patients who are tested for malaria at four health facilities located in malaria endemic areas of Kisumu and Siaya in western Kenya. The work will be conducted from July to December 2024. The project will compare and evaluate Noul's digital microscopy-based malaria diagnostic solution with rapid diagnostic tests and local microscopy to field-validate the effectiveness of Noul's product as a malaria diagnostic solution.
Dr. Simon Kariuki, the Head of KEMRI/Centre for Global Health Research Malaria Program, in Kisumu said, "WHO recommends confirming malaria through quality-assured microscopy or rapid diagnostic tests in malaria-endemic areas such as western Kenya. There are many challenges with the currently recommended tests for the diagnosis of malaria, and new technology is urgently needed to improve the quality of diagnosis of malaria. We hope that Noul's digital microscopy-based malaria diagnostic solution will greatly improve the effectiveness of malaria diagnosis in the field."
According to the WHO report released last April 2024, 'Digital Malaria Microscopy' is mentioned as a major task that the international community must implement to combat malaria. miLab™ MAL is an automated diagnostic solution which uses artificial intelligence (AI) to improve microscopy by detecting and displaying images of parasites for the laboratory technician. Unlike rapid diagnostic tests (RDTs) that determine infection by antigen-antibody reactions, miLab™ MAL utilizes a morphological diagnostic approach allowing accurate diagnostic testing regardless of the presence of pfhrp2/3 deletions, which are currently spreading across Africa.
Dr. Tae-hwan Kim, the Head of Business Division of Noul, said, "Noul's miLab™ MAL is proving its top-notch diagnostic performance beyond field microscopy in major African countries such as Nigeria, Ghana, and Ethiopia, as reported in several publications. Through the project with the U.S. CDC and KEMRI, Noul plans to establish miLab™ MAL as the best-performing product to solve the global malaria diagnostic problem and prepare a bridgehead for entering the U.S. market based on secured references."
Kenya has about 3.5 million malaria infections per year, with 13 million tests performed annually to diagnose malaria. Western Kenya is a place where quality-assured malaria diagnostic methods are needed for all febrile patients before treatment, and the current diagnostic methods, microscopy and RDTs, pose several challenges making it difficult to accurately diagnose malaria. This is why new digital technology, Noul's miLab™ MAL, is needed to improve malaria diagnosis.
About Noul
On-Device Healthcare Company, Noul is recognized for its innovative technology as the first AI-based diagnostic platform company in the blood and cancer sector, with miLab™ platform introduced as "the most advanced digital microscope and fully integrated bench-top platform" in UNITAID's report in 2022.
Website https://noul.kr/en/
